Methyltrienolone is 17α-alkylated for oral bioavailability — a structural feature directly responsible for the most severe hepatotoxic class of AAS. Cholestatic injury, peliosis hepatis, and hepatic adenoma are all class-documented. Cycle length must be capped (typically < 6-8 weeks); LFTs (ALT, AST, GGT, bilirubin) baseline + every 2 weeks on cycle. Stop immediately on ALT/AST > 3× ULN or symptomatic jaundice.
Methyltrienolone
Extensively Studied17α-methylated trenbolone — the oral version of the most potent mainstream injectable AAS, sold via gray-market UGLs and used in lab… | AAS · Oral
Aliases (6)
▸ Cycle structure & PCT AAS oral
Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.
On the last dose, the ester clears over its half-life window (enanthate = est. 7 days). PCT begins after the active compound has cleared.
Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).
▸ Overview TL;DR
17α-methylated trenbolone — the oral version of the most potent mainstream injectable AAS, sold via gray-market UGLs and used in lab science as the radioligand R1881. Combines tren-class psychiatric/CV/HPG damage with 17α-methyl class-leading hepatotoxicity (cholestasis, peliosis hepatis, adenoma risk). Never FDA-approved in 60+ years. Pre-contest bodybuilding lore caps use at 1-2 weeks for this exact reason. Categorical SKIP-PERMANENT for any user including Dylan; sits in the "essentially universally bad idea" AAS tier alongside fluoxymesterone and methyltestosterone.
▸ Mechanism of action
Methyltrienolone is trenbolone (estra-4,9,11-trien-3-one) with a 17α-methyl group bolted on. That single structural change does two things:
- Makes it orally bioavailable — the methyl group blocks first-pass hepatic deactivation that destroys oral testosterone and oral trenbolone. This is the same trick used in methyltestosterone, fluoxymesterone, oxandrolone, stanozolol, and methandrostenolone (Dianabol).
- Makes it catastrophically hepatotoxic — the same 17α-methyl group is the structural feature responsible for the entire 17α-alkylated class's class-leading hepatic damage profile (cholestatic injury, peliosis hepatis, hepatic adenoma, hepatocellular carcinoma).
Layered onto trenbolone's already-extreme pharmacology:
- AR binding affinity ~5× testosterone (per parent trenbolone) — methyltrienolone retains and arguably exceeds this; in laboratory binding studies R1881 is the gold-standard AR radioligand because of its high affinity and minimal cross-reactivity.
- Glucocorticoid receptor (GR) agonist — drives anxiety, sleep destruction, cardiovascular damage, connective-tissue catabolism (the "tren-class" subjective profile).
- Progestogenic activity — prolactin elevation, gynecomastia risk that aromatase inhibitors don't address.
- Non-aromatizing — does not convert to estradiol, removing estrogen's cardioprotective effects (HDL crash, vascular endothelial damage).
- 5α-reductase resistant — does not convert to DHT but is itself extraordinarily androgenic.
- HPG suppression: among the most severe of any AAS — LH/FSH crash within days; recovery post-cycle slow and uncertain.
The clean way to think about methyltrienolone's risk profile: take trenbolone's already-extreme cost profile and add a 17α-methyl group's hepatotoxicity on top. There is no harm-reduction win anywhere in the molecule.
▸ Pharmacokinetics No data
▸Research indications5 use cases
Glucocorticoid receptor (GR) agonist
Most effectivedrives anxiety, sleep destruction, cardiovascular damage, connective-tissue catabolism (the "tren-class" subjective profile).
Progestogenic activity
Effectiveprolactin elevation, gynecomastia risk that aromatase inhibitors don't address.
Non-aromatizing
Effectivedoes not convert to estradiol, removing estrogen's cardioprotective effects (HDL crash, vascular endothelial damage).
5α-reductase resistant
Moderatedoes not convert to DHT but is itself extraordinarily androgenic.
HPG suppression: among the most severe of any AAS
ModerateLH/FSH crash within days; recovery post-cycle slow and uncertain.
▸Quality indicators4 checks
▸ What to expect Generic
- 1Week 1-2Frontload phase. Strength gains start; appetite up.
- 2Week 3-4Visible muscle fullness and recovery acceleration.
- 3Week 5-8Peak performance window. Monitor blood pressure + libido.
- 4Post-cyclePCT week 1-4. Bloodwork at week 6 post-cycle.
▸ Side effects + safety
- Common (>10% users): Insomnia, night sweats, severe mood lability, irritability, elevated BP, elevated resting HR, sexual dysfunction (mid-cycle ED), severe HPG suppression (universal at any meaningful dose), ALT/AST elevation within first 1-2 weeks, water retention modest.
- Less common (1-10%): Cholestatic jaundice (yellowing, dark urine, pruritus), gynecomastia (progestogenic — AI does not address), aggression incidents, panic-attack-like episodes, severe acne, accelerated androgenic alopecia, kidney function decline, prostate symptoms.
- Rare-serious (<1% but worth knowing):
- Peliosis hepatis — blood-filled cystic lesions in the liver that can rupture catastrophically. 17α-methyl AAS are the primary pharmacologic cause; methyltrienolone is among the highest-risk in the class given its potency.
- Hepatic adenoma / hepatocellular carcinoma — documented with prolonged 17α-methyl AAS use; methyltrienolone's potency means meaningful exposure happens at lower mg-doses than other 17α-AAS.
- Acute liver failure — case reports exist for the 17α-methyl class with cholestatic liver failure progressing to ICU admission.
- Cardiac event (MI, arrhythmia, cardiomyopathy) — HDL crash + hypertension + erythrocytosis + GR activation stack acutely on-cycle.
- Acute kidney injury — case reports in the 19-nor / tren-class.
- Psychotic episode, manic episode, suicidal ideation — vulnerable users.
- Persistent post-cycle hypogonadism — failure to recover endogenous T after even short methyltrienolone exposures, given tren-class HPG suppression severity.
- Tren cough analog — some users report acute respiratory reactions, though injection-route tren cough is not directly applicable to oral mtren.
- Specific watch periods:
- First 7 days: liver enzymes (ALT/AST/GGT/bilirubin) — methyltrienolone hits hepatic injury thresholds fastest of any commonly-discussed AAS.
- Any RUQ pain, jaundice, dark urine, pruritus, or unexplained fatigue is an emergency stop.
- First 4 weeks: psychiatric side effects peak (sleep, mood).
- Mid-cycle through PCT: lipid panel, cardiac surveillance, kidney function.
- 6-12 months post-cycle: ASIH may persist; some users never recover.
▸Interactions7 compounds
- Other 17α-alkylated orals (methyltestosterone, oxandrolone, stanozolol, methandrostenolone, fluoxymesterone):Avoidhepatotoxicity additive and often catastrophic.
- Other AAS:Avoidstacks tren-class CV/HPG damage non-linearly.
- Stimulants (modafinil, amphetamines, high-dose caffeine):Avoidadditive cardiovascular load.
- Alcohol:Avoidadditive hepatic stress (n/a for Dylan but noted for class context).
- NSAIDs (chronic):Avoidadditive hepatic + renal stress.
- SSRIs / antidepressants:Avoidunpredictable interaction with AAS-mood axis.
- Acetaminophen / paracetamol:Avoidadditive hepatic stress on a 17α-methyl backbone is particularly poorly tolerated.